Metastatic Prostate Cancer Clinical Trials in New York, New York

6 studies are recruiting for metastatic prostate cancer in New York, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study of Tarlatamab for People With Prostate Cancer

   The researchers are doing this study to find out whether tarlatamab is an effective treatment for Delta-like Protein 3 (DLL3)-positive prostate cancer that has spread to other parts of your body (metastasized) and has either come back after treatment (relapsed) or not responded to treatment (refrac…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York

   Locations

   10 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT07111507 on ClinicalTrials.gov

2. Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer

   The main purpose of this study is to assess the safety and tolerability of AZD0516 as monotherapy and/or in combination with other anti-cancer agents for treatment of metastatic prostate cancer.

   Stage

   Phase 1

   Ages

   18 to 130

   Site

   Research Site, New York, New York

   Locations

   52 in total

   Run by

   AstraZeneca

   See if you can join NCT07181161 on ClinicalTrials.gov

3. Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer

   The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of multiple anti-cancer agents in participants with metastatic prostate cancer.

   Stage

   Phase 1

   Ages

   18 to 99

   Site

   Research Site, New York, New York

   Locations

   37 in total

   Run by

   AstraZeneca

   See if you can join NCT07590934 on ClinicalTrials.gov

4. Study of ORIC-944 in Patients With Metastatic Prostate Cancer

   The purpose of this study is to establish the safety and preliminary antitumor activity of ORIC-944 as a single agent and in combinations with ARPIs in patients with metastatic prostate cancer.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Memorial Sloane Kettering Cancer Center, New York, New York

   Locations

   27 in total

   Run by

   ORIC Pharmaceuticals

   See if you can join NCT05413421 on ClinicalTrials.gov

5. Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer

   This is a prospective, open-label, multi-center seamless phase II to phase III randomized clinical trial designed to compare SST with or without PET-directed local therapy in improving the castration-resistant prostate cancer-free survival (CRPC-free survival) for Veterans with oligometastatic pros…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   VA NY Harbor Healthcare System, New York, NY, New York, New York

   Locations

   20 in total

   Run by

   VA Office of Research and Development

   See if you can join NCT04787744 on ClinicalTrials.gov

6. Study of AZD0754 in Participants With Metastatic Prostate Cancer

   The purpose of this study is to evaluate the safety, tolerability, and antitumour activity of AZD0754 CAR T-cell therapy in participants with metastatic prostate cancer.

   Stage

   Phase 1

   Ages

   18 to 130

   Site

   Research Site, New York, New York

   Locations

   15 in total

   Run by

   AstraZeneca

   See if you can join NCT06267729 on ClinicalTrials.gov